Phase 1 Trial of Atezolizumab Plus Trimodal Therapy in Patients With Localized Muscle-Invasive Bladder Cancer
- 6 January 2021
- journal article
- research article
- Published by Elsevier BV in International Journal of Radiation Oncology*Biology*Physics
- Vol. 110 (3), 738-741
- https://doi.org/10.1016/j.ijrobp.2020.12.033
Abstract
No abstract availableFunding Information
- Roche
This publication has 10 references indexed in Scilit:
- Anisotropic Bladder Planning Target Volume in Bladder Radiation TherapyPractical Radiation Oncology, 2019
- Bladder-Sparing Hypofractionated Intensity Modulated Radiation Therapy plus Weekly Gemcitabine in Patients with Invasive Bladder CancerInternational Journal of Radiation Oncology*Biology*Physics, 2018
- Dose-limiting Urinary Toxicity With Pembrolizumab Combined With Weekly Hypofractionated Radiation Therapy in Bladder CancerInternational Journal of Radiation Oncology*Biology*Physics, 2018
- Immune checkpoint inhibition-related colitis: symptoms, endoscopic features, histology and response to managementESMO Open, 2018
- Pembrolizumab as Second-Line Therapy for Advanced Urothelial CarcinomaThe New England Journal of Medicine, 2017
- Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paperAnnals of Oncology, 2015
- Radiation meets immunotherapy – a perfect match in the era of combination therapy?International Journal of Radiation Biology, 2015
- Anti-PD-L1 antibody active in metastatic bladder cancerThe Lancet Oncology, 2015
- MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancerNature, 2014
- Hypofractionated Intensity Modulated Radiation Therapy in Combined Modality Treatment for Bladder Preservation in Elderly Patients With Invasive Bladder CancerInternational Journal of Radiation Oncology*Biology*Physics, 2014